Gennex Laboratories [GENNEX] vs Sun Pharmaceutical [SUNPHARMA] Detailed Stock Comparison
Gennex Laboratories
BSE
Loading...
Sun Pharmaceutical
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Gennex Laboratories wins in 5 metrics, Sun Pharmaceutical wins in 14 metrics, with 0 ties. Sun Pharmaceutical appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Gennex Laboratories | Sun Pharmaceutical | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 16.41 | 37.73 | Gennex Laboratories |
| Price-to-Book Ratio | 1.18 | 5.42 | Gennex Laboratories |
| Debt-to-Equity Ratio | 13.93 | 3.26 | Sun Pharmaceutical |
| PEG Ratio | 2.80 | -1.94 | Sun Pharmaceutical |
| EV/EBITDA | 15.81 | 23.98 | Gennex Laboratories |
| Profit Margin (TTM) | 11.46% | 19.29% | Sun Pharmaceutical |
| Operating Margin (TTM) | 13.37% | 24.34% | Sun Pharmaceutical |
| EBITDA Margin (TTM) | 13.37% | 24.34% | Sun Pharmaceutical |
| Return on Equity | 9.31% | 15.08% | Sun Pharmaceutical |
| Return on Assets (TTM) | 7.08% | 11.87% | Sun Pharmaceutical |
| Free Cash Flow (TTM) | $-197.44M | $119.44B | Sun Pharmaceutical |
| Dividend Yield | N/A | 1.26% | N/A |
| 1-Year Return | -41.07% | -14.60% | Sun Pharmaceutical |
| Price-to-Sales Ratio (TTM) | 2.16 | 7.28 | Gennex Laboratories |
| Enterprise Value | $2.75B | $3,678.87B | Sun Pharmaceutical |
| EV/Revenue Ratio | 1.92 | 6.84 | Gennex Laboratories |
| Gross Profit Margin (TTM) | 35.05% | 79.58% | Sun Pharmaceutical |
| Revenue per Share (TTM) | $7 | $224 | Sun Pharmaceutical |
| Earnings per Share (Diluted) | $0.78 | $43.23 | Sun Pharmaceutical |
| Beta (Stock Volatility) | 0.31 | 0.28 | Sun Pharmaceutical |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Gennex Laboratories vs Sun Pharmaceutical Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Gennex Laboratories | -0.55% | 8.38% | 11.50% | 2.32% | -9.28% | -25.32% |
| Sun Pharmaceutical | 1.44% | 2.80% | 3.33% | -2.89% | -7.84% | -13.69% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Gennex Laboratories | -41.07% | 96.92% | 228.21% | 181.32% | 759.06% | 975.63% |
| Sun Pharmaceutical | -14.60% | 70.78% | 218.03% | 80.00% | 690.16% | 2,608.73% |
News Based Sentiment: Gennex Laboratories vs Sun Pharmaceutical
Gennex Laboratories
News based Sentiment: MIXED
Gennex Laboratories experienced a stock price reversal and reported positive Q1 FY2026 results, but continues to face significant long-term declines and saw a large insider sell transaction. These mixed signals create a complex investment picture, making October a noteworthy but not transformative month for the company.
Sun Pharmaceutical
News based Sentiment: MIXED
October was a month of significant contrasts for Sun Pharma. While the company demonstrated revenue growth and made strategic acquisitions, the imposition of a 100% US tariff on Indian pharmaceuticals presents a major headwind. This combination of positive and negative developments creates a mixed investment outlook.
Performance & Financial Health Analysis: Gennex Laboratories vs Sun Pharmaceutical
| Metric | GENNEX | SUNPHARMA |
|---|---|---|
| Market Information | ||
| Market Cap | ₹3.11B | ₹4.01T |
| Market Cap Category | Small cap | Large cap |
| 10 Day Avg. Volume | 642,874 | 3,168,435 |
| 90 Day Avg. Volume | 571,621 | 2,778,768 |
| Last Close | ₹12.73 | ₹1,654.70 |
| 52 Week Range | ₹10.84 - ₹19.00 | ₹1,548.00 - ₹1,947.00 |
| % from 52W High | -33.00% | -15.01% |
| All-Time High | ₹29.00 (Sep 16, 2024) | ₹1,960.35 (Sep 30, 2024) |
| % from All-Time High | -56.10% | -15.59% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.21% | 0.10% |
| Quarterly Earnings Growth | 0.08% | -0.20% |
| Financial Health | ||
| Profit Margin (TTM) | 0.11% | 0.19% |
| Operating Margin (TTM) | 0.13% | 0.24% |
| Return on Equity (TTM) | 0.09% | 0.15% |
| Debt to Equity (MRQ) | 13.93 | 3.26 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹10.85 | ₹300.99 |
| Cash per Share (MRQ) | ₹2.40 | ₹108.88 |
| Operating Cash Flow (TTM) | ₹-75,467,000 | ₹110.84B |
| Levered Free Cash Flow (TTM) | ₹181.23M | ₹109.29B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 1.26% |
| Last 12-Month Dividend | ₹0.00 | ₹21.00 |
Valuation & Enterprise Metrics Analysis: Gennex Laboratories vs Sun Pharmaceutical
| Metric | GENNEX | SUNPHARMA |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 16.41 | 37.73 |
| Forward P/E | N/A | 49.91 |
| PEG Ratio | 2.80 | -1.94 |
| Price to Sales (TTM) | 2.16 | 7.28 |
| Price to Book (MRQ) | 1.18 | 5.42 |
| Market Capitalization | ||
| Market Capitalization | ₹3.11B | ₹4.01T |
| Enterprise Value | ₹2.75B | ₹3.68T |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 1.92 | 6.84 |
| Enterprise to EBITDA | 15.81 | 23.98 |
| Risk & Other Metrics | ||
| Beta | 0.31 | 0.28 |
| Book Value per Share (MRQ) | ₹10.85 | ₹300.99 |
Financial Statements Comparison: Gennex Laboratories vs Sun Pharmaceutical
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | GENNEX | SUNPHARMA |
|---|---|---|
| Revenue/Sales | ₹341.78M | ₹137.86B |
| Cost of Goods Sold | ₹221.97M | ₹28.15B |
| Gross Profit | ₹119.81M | ₹109.71B |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹45.68M | ₹33.72B |
| EBITDA | ₹73.49M | ₹47.66B |
| Pre-Tax Income | ₹58.66M | ₹31.73B |
| Income Tax | ₹8.50M | ₹8.70B |
| Net Income (Profit) | ₹50.16M | ₹22.93B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | GENNEX | SUNPHARMA |
|---|---|---|
| Cash & Equivalents | ₹545.89M | ₹102.69B |
| Total Current Assets | ₹1.81B | ₹526.24B |
| Total Current Liabilities | ₹445.55M | ₹181.94B |
| Long-Term Debt | ₹168.93M | ₹3.58B |
| Total Shareholders Equity | ₹1.95B | ₹724.86B |
| Retained Earnings | ₹562.59M | ₹578.62B |
| Property, Plant & Equipment | ₹88.69M | ₹100.36B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | GENNEX | SUNPHARMA |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | GENNEX | SUNPHARMA |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 642,874 | 3,168,435 |
| Average Daily Volume (90 Day) | 571,621 | 2,778,768 |
| Shares Outstanding | 227.45M | 2.40B |
| Float Shares | 132.11M | 1.06B |
| % Held by Insiders | 0.31% | 0.56% |
| % Held by Institutions | 0.00% | 0.25% |
Dividend Analysis & Yield Comparison: Gennex Laboratories vs Sun Pharmaceutical
| Metric | GENNEX | SUNPHARMA |
|---|---|---|
| Last 12-Month Dividend | ₹0.00 | ₹21.00 |
| Last 12-Month Dividend Yield | N/A | 1.26% |
| 3-Year Avg Annual Dividend | ₹0.00 | ₹14.67 |
| 3-Year Avg Dividend Yield | N/A | 0.46% |
| 3-Year Total Dividends | ₹0.00 | ₹44.00 |
| Ex-Dividend Date | N/A | Jul 07, 2025 |